Although it is not implicated as an oncogenic driver, AXL is overexpressed in several hematologic and solid malignancies, such as acute myeloid leukemia, non-small-cell lung cancer, gastric and colorectal adenocarcinoma, as well as prostate and breast cancer.10 This evidence concerns the gene AXL and colorectal adenocarcinoma.